Drug Research
IBM Patents Machine Learning Model for Pharmaceutical Drug Discovery
IBM announced that its scientists have been granted a patent on machine learning models to predict therapeutic indications and side effects from various drug information sources. IBM Research has implemented a cognitive association engine to identify...
Drug Research
Pharnext Announces R&D Agreement with Galapagos to Generate a New Pipeline of Synergistic Drug Combinations
Pharnext SA , a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases announced a research and development (R&D) agreement with Galapagos NV. The main goal of this agreement is...
Drug Research
Titan Pharmaceuticals Receives Fda Communication On Ropinirole Implant Investigational New Drug Application
Titan Pharmaceuticals, Inc ,a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery platform announced that the U.S. FDA has completed its initial review of the ropinirole implant Investigational New...
Drug Research
Sanofi and Regeneron Announce First Approval of KevzaraTM for the Treatment of Moderately
Sanofi and Regeneron Pharmaceuticals, Inc announced that Health Canada approved KevzaraTM (sarilumab), an interleukin-6 (IL-6) receptor antibody. For the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate...
Drug Research
Novo Nordisk enters collaboration with University of Oxford on type 2 diabetes and invests GBP 115m in new research centre
University of Oxford and Novo Nordisk announced a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk and University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes....
Drug Research
IBM Watson Health and Lundbeck form collaboration on technology for developing innovative medicine
H. Lundbeck A/S is collaborating with IBM's Watson Health to accelerate the development of innovative medicines to treat psychiatric and neurological disorders. The collaboration will combine Lundbeck's expertise in the treatment of psychiatric and neurological disorders...
Drug Research
PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases
PharmAthene, Inc. and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, announced the signing of a definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction. Altimmune's current investors include Novartis Venture...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.